Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two Arm Randomised, Open-label Study to Investigate the Persistence of Autoantibody Neutralisation, the Safety, and Pharmacokinetics of BC 007 in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) and Autoantibodies Directed Against the beta1 Adrenergic Receptor

NCT04192214 is registered in ClinicalTrials.gov with Berlin Cures GmbH as lead sponsor.

NCT NCT04192214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04192214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two Arm Randomised, Open-label Study to Investigate the Persistence of Autoantibody Neutralisation, the Safety, and Pharmacokinetics of BC 007 in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) and Autoantibodies Directed Against the beta1 Adrenergic Receptor
Lead sponsor
Berlin Cures GmbH
Phase
Phase 2
Overall status
Completed
Start date
March 29, 2019
Completion date
December 6, 2022
Enrollment
30 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

autoantibodies, cardiomyopathy, dilated, heart failure